Galectin-3 expression in peripheral blood mononuclear cells of chronic hepatitis B patients treated with pegylated interferon alpha-2a.
- VernacularTitle:聚乙二醇干扰素α-2a对慢性乙型肝炎患者外周血单个核细胞Galectin-3表达的影响
- Author:
Yi LI
1
;
Long YU
;
Xiaoling WU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; Case-Control Studies; Female; Galectin 3; metabolism; Hepatitis B, Chronic; drug therapy; metabolism; Humans; Interferon-alpha; therapeutic use; Leukocytes, Mononuclear; metabolism; Male; Polyethylene Glycols; therapeutic use; Recombinant Proteins; therapeutic use; Treatment Outcome; Young Adult
- From: Chinese Journal of Hepatology 2014;22(5):336-339
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the relationship between therapeutic efficacy of pegylated interferon alpha-2a (Peg-IFNa-2a) in patients with chronic hepatitis B (CHB) and expression of Galectin-3 in peripheral blood mononuclear cells (PBMCs).
METHODSFifty CHB patients treated with a 48-week course of Peg-IFNa-2a (180 mug/week, subcutaneous) were divided into groups according to treatment response, with 14 patients in the 24-week responder group, 21 patients in the 48-week responder group and 15 patients in the non-responder groups. Twenty healthy volunteers served as the normal control group. Gene and protein expression of Galectin-3 in PBMCs was detected by PCR and westen blotting.
RESULTSPBMC expression of Galectin-3 was significantly higher in the effective treatment (responders) group compared to the control group and the non-responder group. In addition, the 24-week responders had significantly higher than the 48-week responders, and the 48-week responders had significantly higher Galectin-3 expression than the non-responders at 24 weeks.
CONCLUSIONPeg-IFNa-2a may inhibit HBV DNA replication by up-regulating the expression of Galectin-3 in PBMCs.
